HUMAYUN KABIR: Open Payments
NPI 1821638438 · CHESAPEAKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,364 in 145 payments from 16 companies in 2025. Trend: 2023 $1,682 · 2024 $1,894 · 2025 $2,364
Food & beverage: $2,364
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $453 |
| E.R. Squibb & Sons, L.L.C. | 18 | $318 |
| Otsuka America Pharmaceutical, Inc. | 14 | $245 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $239 |
| Neurocrine BioSciences, Inc. | 16 | $224 |
| Alkermes, Inc. | 10 | $204 |
| Teva Pharmaceuticals USA, Inc. | 11 | $136 |
| Vanda Pharmaceuticals Inc. | 8 | $135 |
| Janssen Pharmaceuticals, Inc | 5 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $102 |
Products named: VRAYLAR, COBENFY, CAPLYTA, INGREZZA, REXULTI, ARISTADA, AUSTEDO XR, FANAPT.
Industry payments across VA — which companies pay providers there.
